First up this week is a team at Wilmer Cutler Pickering Hale and Dorr that helped pharmaceutical client Exelixis Inc. protect the validity of the patents underlying Cabometyx and Cometriq, two drugs to treat kidney, liver and thyroid cancers that generated about $1.6 billion in sales in 2023. The case came in the context of MSN Pharmaceuticals Inc. seeking approval of a generic version of Cabometyx. After a four-day bench trial last October, U.S. District Senior Judge Richard Andrews in Delaware this week sided with Exelixis on the validity of three patents that MSN stipulated its proposed generic version infringed upon. The judge found a fourth patent valid, but not infringed. The Wilmer team includes Bill Lee, Lisa Pirozzolo, Emily Whelan, Kevin Prussia, Marissa Lalli, Jonathan Cox and Timothy Cook.